95 related articles for article (PubMed ID: 2841390)
1. [Clinical experiences in tumor-oriented anti-cancer drugs].
Ohsawa N
Nihon Naika Gakkai Zasshi; 1988 Mar; 77(3):313-7. PubMed ID: 2841390
[No Abstract] [Full Text] [Related]
2. [Bestrabacil: a possible target-oriented anticancer agent].
Ohsawa N; Yamazaki Z; Wagatsuma T; Isurugi K
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2115-24. PubMed ID: 6548354
[TBL] [Abstract][Full Text] [Related]
3. Prednimustine for prostate cancer therapy.
Slack NH; Murphy GP
Compr Ther; 1979 Sep; 5(9):54-7. PubMed ID: 487742
[No Abstract] [Full Text] [Related]
4. [Clinical effects of bestrabucil (KM2210) in bladder cancer].
Nasu Y; Saegusa M; Ochi J; Hara M; Akagi T; Obama T; Yoshimoto J; Matsumura Y; Ohmori H; Tsushima T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3155-6. PubMed ID: 3674900
[No Abstract] [Full Text] [Related]
5. [Tumor-oriented anti-cancer agent with estrogen as a carrier].
Ohsawa N; Yamazaki Z
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1065-71. PubMed ID: 3291767
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of bestrabucil (KM 2210)].
Kamei H; Takenaka K; Goto T; Suga S; Fugiwara A; Nakao I; Agatsuma T; Fujita K; Isurugi K; Kubota T
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2208-15. PubMed ID: 3755019
[TBL] [Abstract][Full Text] [Related]
7. [Early phase II trial of bestrabucil in hematological malignancies].
Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
[TBL] [Abstract][Full Text] [Related]
8. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
Mittelman A; Catane R; Murphy GP
Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
[TBL] [Abstract][Full Text] [Related]
9. [A new anti-cancer agent, bestrabucil (KM 2210): I. Concentration in the serum and tissue in urogenital tumors].
Nasu Y; Saegusa M; Hara M; Ochi J; Akagi T; Obama T; Tsushima T; Yoshimoto J; Ozaki Y; Matsumura Y
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1116-21. PubMed ID: 3566306
[TBL] [Abstract][Full Text] [Related]
10. Prednimustine: the rationale for clinical development.
Schein PS; Cavalli F
Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-2. PubMed ID: 3952515
[No Abstract] [Full Text] [Related]
11. Prednimustine.
Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-44. PubMed ID: 3952516
[No Abstract] [Full Text] [Related]
12. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
Ueda T; Sakai K; Morimoto K; Nakatani S
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
[TBL] [Abstract][Full Text] [Related]
13. A phase III study of prednimustine (LEO 1031) in advanced breast cancer. A preliminary report.
Rørth M; Løber J; Dombernowsky P; Krusenstjerna-Hofstrom D; Mattsson W; Mouridsen HT
Eur J Cancer (1965); 1980; Suppl 1():137-40. PubMed ID: 7032923
[No Abstract] [Full Text] [Related]
14. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
J Urol; 1979 Jun; 121(6):763-5. PubMed ID: 458947
[TBL] [Abstract][Full Text] [Related]
15. The antitumor effect of prednimustine in vitro and in vivo.
Hartley-Asp B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):3-7. PubMed ID: 3952519
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
Loos U; Musch E; Malek M; Riedel E
Oncology; 1991; 48(4):334-42. PubMed ID: 1891177
[TBL] [Abstract][Full Text] [Related]
17. [Targeting therapy of cancer, using hormones as carriers].
Ohsawa N
Nihon Rinsho; 1989 Jun; 47(6):1417-22. PubMed ID: 2770003
[No Abstract] [Full Text] [Related]
18. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report.
Gaynon PS; Baum ES; Krivit W; Hammond D
Cancer Treat Rep; 1982 Jul; 66(7):1583-4. PubMed ID: 6284362
[No Abstract] [Full Text] [Related]
19. [Quantitative assay of growth response of clinical breast cancer cells against E2 or E2-conjugated drugs].
Matsuoka H; Furusawa M; Sugimachi K
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1705-6. PubMed ID: 8060151
[No Abstract] [Full Text] [Related]
20. Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings].
Catane R
Cancer Treat Rep; 1978 Aug; 62(8):1264-5. PubMed ID: 688269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
